Sirnaomics (2257.HK)

Executive Summary

Sirnaomics is a clinical-stage RNA therapeutics company pioneering RNAi and mRNA-based drugs for oncology and other diseases with high unmet need. The company achieved a landmark positive Phase IIb outcome for its lead candidate STP705, demonstrating the platform's potential and de-risking its pipeline. With a proprietary delivery system enabling targeted gene silencing, Sirnaomics has built a diverse pipeline including STP705 for non-melanoma skin cancer, STP707 for solid tumors, and STP122G for influenza. The company maintains a dual presence in the U.S. and China, leveraging global clinical development capabilities. Despite being pre-revenue, its robust technology platform and early clinical validation position it as a notable player in the RNA therapeutics space. Key upcoming catalysts include data readouts from Phase II studies and potential partnership announcements that could validate its platform and accelerate development.

Upcoming Catalysts (preview)

• Q3 2026Phase II data readout for STP705 in basal cell carcinoma (BCC) or squamous cell carcinoma70% success
• Q4 2026Phase I/II interim data for STP707 in advanced solid tumors50% success
• H2 2026Potential strategic partnership or licensing deal for mRNA vaccine or RNAi platform40% success